WO2009104051A3 - Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine - Google Patents

Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine Download PDF

Info

Publication number
WO2009104051A3
WO2009104051A3 PCT/IB2008/003661 IB2008003661W WO2009104051A3 WO 2009104051 A3 WO2009104051 A3 WO 2009104051A3 IB 2008003661 W IB2008003661 W IB 2008003661W WO 2009104051 A3 WO2009104051 A3 WO 2009104051A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
methods
therapeutics
treatment
prostate cancer
Prior art date
Application number
PCT/IB2008/003661
Other languages
French (fr)
Other versions
WO2009104051A2 (en
Inventor
Patrick Y. Lu
Ashgar Ghias
David Evans
Original Assignee
Lu Patrick Y
Ashgar Ghias
David Evans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lu Patrick Y, Ashgar Ghias, David Evans filed Critical Lu Patrick Y
Publication of WO2009104051A2 publication Critical patent/WO2009104051A2/en
Publication of WO2009104051A3 publication Critical patent/WO2009104051A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Ceramic Engineering (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides compositions and methods for treatment of prostate cancer using siRNA cocktail sequences targeting multiple disease causing genes, and a combined regimen with both RNAi therapeutics and EEMP encapsulated magnetic nanoparticle therapeutics. The invention includes: 1) The algorithm for designing siRNA drug API (active pharmaceutical ingredient); 2)The compositions of multiple siRNA inhibiting expression of the multiple cancer causing genes; 3) The methods of designing siRNA duplexes with different lengths, different ends and to target the same genes from both human and mouse cells; 4) The methods of formulating various siRNA cocktail which are able to inhibit tumorigenic and angiogenesis; 5) The methods of using histidine-lysine copolymer (HKP), PAMAM dendrimer and Liposomal (DOTAP) carrier to enhance siRNA delivery into the cutaneous tissue; and 6) The methods of using two disease relevant mouse xenograft models to validate the siRNA cocktail for its efficacy on controlling tumor growth.
PCT/IB2008/003661 2007-12-31 2008-12-31 Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine WO2009104051A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US623107P 2007-12-31 2007-12-31
US60/006,231 2007-12-31

Publications (2)

Publication Number Publication Date
WO2009104051A2 WO2009104051A2 (en) 2009-08-27
WO2009104051A3 true WO2009104051A3 (en) 2010-06-10

Family

ID=40985986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003661 WO2009104051A2 (en) 2007-12-31 2008-12-31 Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine

Country Status (1)

Country Link
WO (1) WO2009104051A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
EP2475372B2 (en) 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application
US9642873B2 (en) * 2010-05-04 2017-05-09 Sirnaomics, Inc. Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application
CA2801535C (en) 2010-06-04 2017-05-30 Hough Ear Institute Composition and method for inner ear sensory hair cell regeneration or replacement
DE102011100581A1 (en) * 2011-05-04 2012-11-08 Eberhard-Karls-Universität Tübingen Universitätsklinikum Treatment of hyperproliferative diseases of the genitourinary tract
CN105363042B (en) * 2015-10-21 2022-05-06 圣诺生物医药技术(苏州)有限公司 Pharmaceutical composition and application thereof
WO2020144583A1 (en) * 2019-01-08 2020-07-16 Olix Pharmaceuticals, Inc. Cell-penetrating tripodal interfering rna
CN113209043B (en) * 2020-01-19 2023-12-15 中山大学孙逸仙纪念医院 Intracellular response nanoparticle loaded with target gene siRNA and preparation method thereof
CN111693619B (en) * 2020-05-18 2021-09-17 中国石油大学(北京) P-mercaptobenzoic acid modified magnetic PAMAM dendritic polymer material
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026172A1 (en) * 2003-02-11 2005-02-03 Immusol, Inc. siRNA libraries optimized for predetermined protein families
US20070190055A1 (en) * 2006-02-16 2007-08-16 Jayakrishna Ambati CCR3 inhibition for ocular angiogenesis and macular degeneration
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026172A1 (en) * 2003-02-11 2005-02-03 Immusol, Inc. siRNA libraries optimized for predetermined protein families
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
US20070190055A1 (en) * 2006-02-16 2007-08-16 Jayakrishna Ambati CCR3 inhibition for ocular angiogenesis and macular degeneration
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY

Also Published As

Publication number Publication date
WO2009104051A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
WO2009104051A3 (en) Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
Duan et al. Recent advances in drug delivery systems for targeting cancer stem cells
Anselmo et al. Nanoparticles in the clinic: An update
Shen et al. Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy
Feng et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
He et al. Nanoscale coordination polymers codeliver chemotherapeutics and siRNAs to eradicate tumors of cisplatin-resistant ovarian cancer
Costa et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma
Cui et al. Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer
Strumberg et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors
Hsu et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Awasthi et al. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
Kuang et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting
Merkel et al. Nonviral pulmonary delivery of siRNA
Keyvani‐Ghamsari et al. Curcumin effect on cancer cells' multidrug resistance: an update
Beloor et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA
Blanco et al. Molecular-targeted nanotherapies in cancer: enabling treatment specificity
CN107106564A (en) Method and composition for treating the malignant tumour related to KRAS
NZ588583A (en) Novel lipid formulations for nucleic acid delivery
Kaur et al. Cancer treatment therapies: traditional to modern approaches to combat cancers
Guo et al. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
Ortíz et al. Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress
Farra et al. Strategies for delivery of siRNAs to ovarian cancer cells
Ahmad et al. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872553

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008872553

Country of ref document: EP